Ductal Carcinoma In Situ (DCIS)
Risk for all-cause mortality is lower among older women treated for DCIS.
Robustness of dichotomous assessment is important when evaluating stromal features of ductal carcinoma in situ (DCIS), according to a study presented at SABCS 2016.
Routine testing for hormone receptors in tissue obtained in a first needle biopsy for ductal carcinoma in situ (DCIS).
Consensus guideline states that a 2 mm margin is enough to guard against recurrences while reducing need for additional operations for women with DCIS who undergo breast-conserving surgery.
A new technique combines imaging and mathematics to identify aggressive forms of ductal carcinoma in situ (DCIS), or stage 0 breast cancer, from nonaggressive varieties.
Decisions about radiotherapy after breast-conserving surgery for ductal carcinoma in situ can be tailored on the basis of patient factors, tumor biology, and the prognostic score, according to research.
Age, surgery, and radiation were associated with the initiation of tamoxifen after ductal carcinoma in situ (DCIS).
Active surveillance could be a viable alternative to surgery and radiation for select patients with ductal carcinoma in situ (DCIS).
Screening for and treatment of ductal carcinoma in situ (DCIS) is found to prevent subsequent invasive cancer.
Ductal Carcinoma (DCIS) is more likely to become invasive in people over 60 years old.
Researchers estimate the 20-year breast cancer-specific death rate for women diagnosed with ductal carcinoma in situ to be 3.3%.
Women diagnosed with ductal carcinoma in situ have a 20-year breast cancer-specific death rate of 3.3%.
Effect of radiotherapy on survival of women with locally excised ductal carcinoma in situ of the breast: a Surveillance, Epidemiology, and End Results population-based analysisAugust 06, 2015
[OncoTargets and Therapy] This research examines the effect of radiotherapy on overall survival in women with locally excised ductal carcinoma in situ (DCIS).
Although not usually recommended for women with localized cancer undergoing breast-conserving surgery, axillary lymph node evaluation is performed frequently in women with ductal carcinoma in situ (DCIS) breast cancer.
A multigene test was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in situ (DCIS), according to data from a large study.
A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects.
A team of stakeholders has detailed research priorities necessary to address gaps in knowledge about early breast tumors in women.
In women with ductal carcinoma in situ (DCIS), breast-conserving treatment combined with radiotherapy reduces the risk for local recurrence (LR), a recent study indicates.
When ductal carcinoma in situ (DCIS, a preinvasive malignancy of the breast) is described as a high-risk condition rather than cancer, more women report that they would opt for nonsurgical treatments.
No significant difference in five-, eight-year locoregional recurrence rates with, without MRI
Patients more likely to choose nonsurgical option when DCIS is described as breast lesion or abnormal cells.
Physicians have a new resource for managing disease in patients with early-stage breast cancer.
Later-stage breast cancers tend to have more mutations and are more heterogeneous than early-stage cancers. Now, new findings demonstrate that heterogeneity is prevalent even within legions of DCIS.
Despite an enormous degree of intercellular heterogeneity in both ductal carcinoma in situ and invasive ductal carcinoma, recurrent patterns of genomic imbalances determine the evolution from noninvasive to invasive disease in most cases.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|